Figure 5

Adoptive transfer of γ9δ2 T cells enhances CD19BiTE’s antitumor activity in CD19⁺ tumor xenograft-bearing mice. (a) Schematic representation of the experimental schedule. (b) Kaplan–Meier survival curves. Adult NOG mice (16–18 weeks old, male; n = 41) were intravenously (i.v.) inoculated with human Raji/eGFP-fLuc tumor cells (2.5 × 10⁵ cells/mouse). On day five post tumor inoculation, mice received daily treatment of a dose of γ9δ2 T cells (2.5 × 10⁶ cells/mouse, i.v.; n = 5) or two doses of CD19BiTE (250 ng/dose/mouse, i.v.; n = 5) alone, or both (n = 9) for nine consecutive days. Untreated animals serve as controls (n = 22). Survival, the days after tumor inoculation, was followed up. γ9δ2 T cells were expanded from two donors’ peripheral blood mononuclear cells. A single mouse was treated with the γ9δ2 T cells derived from the same donor at different time points. Survival curves were analyzed using the Log-rank (Mantel-Cox) test. ***: p = 0.0002; ****: p < 0.0001. ●: no treatment; ■: treatment of γ9δ2 T cells; ▲: treatment of CD19BiTE; ✖: combination treatment of γ9δ2 T cells + CD19BiTE.